<i>BRAF</i> in Lung Cancers: Analysis of Patient Cases Reveals Recurrent <i>BRAF</i> Mutations, Fusions, Kinase Duplications, and Concurrent Alterations.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 32913992.
- Also identified by DOI 10.1200/PO.17.00172 and PMC identifier 7446447.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Dabrafenib and trametinib are approved for the management of advanced non-small-cell lung cancers (NSCLCs) that harbor <i>BRAF</i> V600E mutations. Small series and pan-cancer analyses have identified non-V600 alterations as therapeutic targets. We sought to examine a large genomic data set to comprehensively characterize non-V600 B<i>RAF</i> alterations in lung cancer. A total of 23,396 patients with lung cancer provided data to assay with comprehensive genomic profiling. Data were reviewed for predicted pathogenic <i>BRAF</i> base substitutions, short insertions and deletions, copy number changes, and rearrangements. Adenocarcinomas represented 65% of the occurrences; NSCLC not otherwise specified (NOS), 15%; squamous cell carcinoma, 12%; and small-cell lung carcinoma, 5%. <i>BRAF</i> was altered in 4.5% (1,048 of 23,396) of all tumors; 37.4% (n = 397) were <i>BRAF</i> V600E, 38% were <i>BRAF</i> non-V600E activating mutations, and 18% were <i>BRAF</i> inactivating. Rearrangements were observed at a frequency of 4.3% and consisted of N-terminal deletions (NTDs; 0.75%), kinase domain duplications (KDDs; 0.75%), and <i>BRAF</i> fusions (2.8%). The fusions involved three recurrent fusion partners: <i>ARMC10</i>, <i>DOCK4,</i> and <i>TRIM24</i>. <i>BRAF</i> V600E was associated with co-occurrence of <i>SETD2</i> alterations, but other <i>BRAF</i> alterations were not and were instead associated with <i>CDKN2A</i>, <i>TP53</i>, and <i>STK11</i> alterations (<i>P</i> < .05). Potential mechanisms of acquired resistance to <i>BRAF</i> V600E inhibition are demonstrated. This series characterized the frequent occurrence (4.4%) of <i>BRAF</i> alterations in lung cancers. Recurrent <i>BRAF</i> alterations in NSCLC adenocarcinoma are comparable to the frequency of other NSCLC oncogenic drivers, such as <i>ALK</i>, and exceed that of <i>ROS1</i> or <i>RET</i>. This work supports a broad profiling approach in lung cancers and suggests that non-V600E BR<i>AF</i> alterations represent a subgroup of lung cancers in which targeted therapy should be considered.